ArticleVaccines2024

Immunogenicity, Safety, and Immune Persistence of One Dose of SARS-CoV-2 Recombinant Adenovirus Type-5 Vectored Vaccine in Children and Adolescents Aged 6-17 Years: An Immunobridging Trial.

Xu Han et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.